|
🐢
|
Acute hemoDynamic effects of rIociguat in patients with puLmonary hypertension Associated with diasTolic heart failurE (DILATE-1): A randomized, double-blind, placebo-controlled, single-dose study
13 auth.
D. Bonderman,
I. Pretsch,
R. Steringer‐Mascherbauer,
P. Jansa,
S. Rosenkranz,
C. Tufaro,
A. Bojic,
C. S. Lam,
R. Frey,
M. O. Kilama,
...
S. Unger,
L. Roessig,
Irene M. Lang
|
7 |
2013 |
7
🐢
|
|
🐜
|
Pulmonary hypertension in heart failure with preserved ejection fraction: a plea for proper phenotyping and further research.
20 auth.
M. Hoeper,
Carolyn S.P. Lam,
J. Vachiéry,
J. Bauersachs,
C. Gerges,
Irene M. Lang,
D. Bonderman,
K. Olsson,
J. Gibbs,
P. Dorfmuller,
...
M. Guazzi,
N. Galiè,
A. Manes,
M. L. Handoko,
A. Vonk-Noordegraaf,
M. Lankeit,
Stavros Konstantinides,
R. Wachter,
C. Opitz,
S. Rosenkranz
|
6 |
2016 |
6
🐜
|
|
🐜
|
Pulmonary Arterial Hypertension-Related Morbidity Is Prognostic for Mortality.
22 auth.
Vallerie V Mclaughlin,
M. Hoeper,
R. N. Channick,
Kelly M Chin,
M. Delcroix,
S. Gaine,
H. Ghofrani,
P. Jansa,
Irene M. Lang,
S. Mehta,
...
T. Pulido,
B. Sastry,
G. Simonneau,
O. Sitbon,
R. Souza,
A. Torbicki,
V. Tapson,
L. Perchenet,
R. Preiss,
P. Verweij,
L. J. Rubin,
N. Galiè
|
6 |
2018 |
6
🐜
|
|
🐜
|
Targeting the Prostacyclin Pathway with Selexipag in Patients with Pulmonary Arterial Hypertension Receiving Double Combination Therapy: Insights from the Randomized Controlled GRIPHON Study
15 auth.
J. Coghlan,
R. Channick,
K. Chin,
L. Di Scala,
N. Galiè,
H. Ghofrani,
M. Hoeper,
Irene M. Lang,
V. McLaughlin,
R. Preiss,
...
L. J. Rubin,
G. Simonneau,
O. Sitbon,
V. Tapson,
S. Gaine
|
6 |
2018 |
6
🐜
|
|
🐜
|
Effect of Selexipag on Morbidity/Mortality in Pulmonary Arterial Hypertension: Results of the GRIPHON Study
15 auth.
Vallerie V Mclaughlin,
R. N. Channick,
Kelly M Chin,
Aline Frey,
Sean Gaine,
A. Ghofrani,
M. Hoeper,
Irene M. Lang,
R. Preiss,
Lewis J. Rubin,
...
G. Simonneau,
Olivier Sitbon,
Mylène Stefani,
V. Tapson,
N. Galiè
|
5 |
2015 |
5
🐜
|
|
🐜
|
Results of an Expert Consensus Survey on the Treatment of Pulmonary Arterial Hypertension with Oral Prostacyclin Pathway Agents.
19 auth.
Vallerie V Mclaughlin,
R. Channick,
T. De Marco,
Harrison W. Farber,
S. Gaine,
N. Galiè,
R. Krasuski,
I. Preston,
R. Souza,
J. G. Coghlan,
...
Robert P. Frantz,
A. Hemnes,
Nick H. Kim,
Irene M. Lang,
D. Langleben,
Mengtao Li,
O. Sitbon,
V. Tapson,
A. Frost
|
4 |
2019 |
4
🐜
|
|
🐢
|
Pulmonary hypertension in chronic heart failure
D. Bonderman,
A. Martischnig,
D. Moertl,
Irene M. Lang
|
4 |
2009 |
4
🐢
|
|
🐜
|
S109 Targeting the prostacyclin pathway in the treatment of connective tissue disease associated pulmonary arterial hypertension (pah): insights from the randomised controlled griphon trial with selexipag
16 auth.
G. Coghlan,
S. Gaine,
R. N. Channick,
L. D. Scala,
N. Galiè,
H. Ghofrani,
H. Ghofrani,
M. Hoeper,
Irene M. Lang,
V. McLaughlin,
...
R. Preiss,
L. J. Rubin,
G. Simonneau,
O. Sitbon,
V. Tapson,
K. Chin
|
0 |
2016 |
0
🐜
|
|
🐜
|
Pulmonary hypertension due to left heart€disease
13 auth.
J. Vachiéry,
R. Tedford,
Stephan Rosenkranz,
M. Palazzini,
Irene M. Lang,
M. Guazzi,
Gerry Coghlan,
Irina E. Chazova,
Teresa De Marco,
N. Galiè,
...
V. McLaughlin,
L. J. Rubin,
G. Simonneau
|
0 |
2019 |
0
🐜
|
